Key Takeaways
- China’s share of global clinical trial initiations has surged from 4 % in 2015 to about 30 % in 2025, while the U.S. share fell from 49 % to 33 % over the same period, driven by markedly faster timelines and lower costs.
- Early‑stage biotech funding in the United States remains tight, especially after cuts to NIH grants, pushing venture capital toward later‑stage, de‑risked assets in cardiometabolic and oncology therapeutic areas.
- Artificial intelligence and related technologies are moving from experimental pilots to embedded tools across the trial lifecycle, supporting protocol design, patient recruitment, monitoring, and data workflows, though human oversight is still essential.
- Adaptive, decentralized, hybrid, and real‑world‑evidence trial designs are gaining traction, reflecting a shift toward patient‑centric research, particularly in rare‑disease and pediatric studies.
- Experts advise sponsors to reassess their global strategies, consider establishing a China‑focused task force, and monitor emerging competitors while leveraging technology to improve efficiency and data quality.
Conference Overview and Context
Arena International’s Outsourcing in Clinical Trials (OCT) East Coast conference took place on 12‑13 May 2026 in New Brunswick, New Jersey. The gathering brought together industry leaders to review the first half of 2026 and forecast the trends likely to shape the remainder of the year. Discussions centered on four interconnected forces: China’s expanding trial footprint, evolving funding dynamics, the maturation of AI‑enabled technologies, and the continual refinement of trial designs.
China’s Rising Influence in Clinical Trials
Peter Barschdorff, Vice President and Head of Deallus (a GlobalData company), highlighted that China’s domination of trial initiation is one of the most durable trends for 2026 and beyond. Data show that while the United States launched roughly half of all new trials in 2015, its share dropped to about one‑third by 2025. Conversely, China’s contribution rose from a mere 4 % to nearly 30 % over the same interval. The practical impact is evident in timelines and costs: Phase I studies in China average seven months, compared with 17 months or more in the U.S., and trial expenses are 32‑52 % lower. Barschdorff cautioned that although the Chinese ecosystem is not yet as finely tuned as U.S.-headquartered operations, the speed‑cost advantage is compelling enough for sponsors to re‑evaluate their geographic strategies and consider establishing a dedicated China task force to monitor competitors and regulatory developments.
Funding Landscape Challenges in the United States
Johnathan Kornstein, Vice President of Rare Disease and Paediatrics at Caidya, noted that the funding environment for early‑stage biotech in the United States remains problematic. The pullback of public funding—particularly cuts to NIH grants observed in early 2025—has exacerbated financing gaps for nascent companies. While venture capital still exists, many firms have become risk‑averse, preferring to invest in later‑stage, de‑risked assets with clear commercial pathways. Cardiometabolic and oncology therapies currently dominate VC interest because they have progressed beyond proof‑of‑concept and present higher likelihoods of market success. Kornstein warned that this shift may leave innovative early‑stage projects struggling to secure seed capital, underscoring the need for alternative financing mechanisms or strategic partnerships.
Technology and AI: From Experimentation to Integration
Kornstein also emphasized that artificial intelligence and related technologies continue to be a major theme in 2026. After several years of pilot projects, AI tools are now transitioning into embedded components of the clinical trial lifecycle. Applications span protocol development, patient recruitment, pattern recognition, risk‑based quality monitoring (RBQM), centralized data management, and overall operational optimization. Despite these advances, AI still requires human oversight; it augments rather than replaces expert judgment. In drug discovery, platforms such as Recursion and Iambic, bolstered by partnerships with NVIDIA, are demonstrating early leadership, but Kornstein stressed that sustained AI enthusiasm will depend on demonstrable clinical success translating the current funding wave into tangible therapeutic outcomes.
Evolving Trial Designs Toward Patient Centricity
Another persistent trend is the evolution of trial designs toward greater flexibility and patient focus. Adaptive trial designs, which allow modifications based on interim data, are being adopted to improve recruitment, retention, and data quality. Kornstein explained that sponsors are increasingly beginning with a deep understanding of the patient journey and disease pathophysiology before finalizing study protocols, thereby aligning the trial more closely with patient needs than with mere data‑collection goals. This mindset shift is especially pronounced in rare‑disease and pediatric research, where traditional endpoints can be difficult to capture. Complementing adaptive approaches, there is growing use of decentralized trials, hybrid models, and real‑world evidence (RWE) gathered via wearables and mobile health technologies, enabling less invasive, continuous data capture and broader participant diversity.
Strategic Implications and Outlook
Overall, while early‑stage U.S. biotech faces headwinds from funding constraints, the global clinical trial sector is being reshaped by China’s accelerated trial execution, the maturing role of AI and digital tools, and a movement toward more patient‑centric, adaptive methodologies. Kornstein concluded that sponsors who successfully navigate these shifts—by reassessing geographic strategies, embracing technology‑driven efficiencies, and adopting flexible trial designs—will be better positioned to maintain relevance and competitiveness. Establishing a small, dedicated team to monitor China’s rapid developments, keeping an eye on emerging competitors, and leveraging AI‑enhanced processes are practical steps recommended by the conference experts. As more organizations achieve proof‑of‑concept in China or integrate advanced technologies, the research landscape appears robust, though the initial hurdle of gaining a foothold in these evolving markets remains a significant challenge.